Copyright © 2001 by the European Society of Cardiology.
Letters to the Editor
Cholesterol reduction, statins and the cytochrome P-450 system. No more recipes please
Basel, Switzerland
References
- Cockcroft JR, Wilkinson IB. Cholesterol reduction, statins and the cytochrome P-450 system (letter). Eur Heart J. 2000;21:15551556
[Free Full Text] - Horsmans Y. Differential metabolism of statins: importance in drugdrug interactions. Eur Heart J Supplements. 1999;1:T7T12
- Yeo KR, Yeo WW, Wallis EJ, Ramsay LE. Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients. Br J Clin Pharm. 1999;48:610615[CrossRef][Web of Science][Medline]
- Mousa O, Brater DC, Sundblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther. 2000;67:267274[CrossRef][Web of Science][Medline]
- Flint OP, Masters BA, Gregg RE, Durham SK. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgerantylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol. 1997;145:99100[CrossRef][Web of Science][Medline]
- Pierno S, De Luca A, Liantonio A, Camerino C, Conte Camerino D. Effects of HMG-CoA reductive inhibitors on excitation-contraction coupling of rat skeletal muscle. Eur J Pharmacol. 1999;364:4348[CrossRef][Web of Science][Medline]
- Simatupang A, Lindenthal B, von Bergmann J, von Bergmann K. Differences in the effect of simvastatin and pravastatin on cholesterol metabolism in patient with hypecholesterolemia (Abstr). Atherosclerosis. 1997;134:220
- Davidson MH, Stein EA, Dujovne CA. The efficacy and six week tolerability of simvastatin 80- and 160mg/day. Am J Cardiol. 1997;79:3842[Web of Science][Medline]
- The Pink Sheet. 1997;:
- Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors. The role of metabolismmonograph for physicians. Arch Intern Med. 2000;160:22732280
[Free Full Text] - Dressrer GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38:4157[CrossRef][Web of Science][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||